Introduction: In America, the prevalence of diabetes mellitus about 8.6% or 21 million adults in 2016. In Indonesia, the prevalence of diabetes mellitus has increased 2% from 2013-2018 for people aged more than 15 years. Vildagliptin was an oral antihyperglycemic drug class Dipeptidyl Peptidase-4 inhibitor which has been approved for use in type 2 diabetes mellitus. However, the benefits and risks of vildagliptin may be different for monotherapy and in combination especially with metformin. This systematic review will explain the efficacy of vildagliptin as monotherapy and vildagliptin in combination with metformin in type 2 diabetes patients. These findings can be used to develop treatment recommendations for type 2 diabetes mellitus sufferers. Methods: Data collection techniques for systematic review using Pubmed and Science direct for terms related to efficacy vildagliptin as single drug and efficacy vildagliptin as combination with metformin in HbA1c, FPG, risk hypoglycemia and weightloss of T2DM. The journals matched with the restriction criteria and PICO. The quality of the journals is tested using GRADE method. Results: Journal searches found 741 journals, 8 of which were eligible for systematic review with high quality journal by GRADE method. The review of 8 journals found that vildagliptin as combination with metformin has good efficacy and can reduce HbA1c (8.1±0.6% to 6.9±0.1%), FPG (141±15mg/dl to 106±4mg/dl), and lower risk of hypoglycemia and weightloss about 4.67±5.8kg for lowdose combination and 4.29±6.7kg for highdose combination. Conclusion: Vildagliptin is more effective in combination with metformin in T2DM patients than vildalgiptin as single drug.